Small-Molecule Inhibition of Androgen Receptor Dimerization as a Strategy against Prostate Cancer

[Image: see text] The clinically used androgen receptor (AR) antagonists for the treatment of prostate cancer (PCa) are all targeting the AR ligand binding pocket (LBP), resulting in various drug-resistant problems. Therefore, a new strategy to combat PCa is urgently needed. Enlightened by the gain-...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Weitao, Yang, Hao, Hu, Chenxian, Liao, Jianing, Gong, Zhou, Zhang, Minkui, Yang, Shuai, Ye, Shangxiang, Lei, Yixuan, Sheng, Rong, Zhang, Zhiguo, Yao, Xiaojun, Tang, Chun, Li, Dan, Hou, Tingjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141604/
https://www.ncbi.nlm.nih.gov/pubmed/37122451
http://dx.doi.org/10.1021/acscentsci.2c01548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141604/
https://www.ncbi.nlm.nih.gov/pubmed/37122451
http://dx.doi.org/10.1021/acscentsci.2c01548

Ejemplares similares